Semaglutide generic
No brand name yet
Dr. Reddy's generic semaglutide injection, cleared by Health Canada in April 2026 and launched in May. Batches were recalled in August for an out of specification impurity and a labelling error.
Semaglutide generic comes from Dr. Reddy's Laboratories and sits in the Incretins class on the board. Route: weekly injection. Use tracked here: Type 2 diabetes in adults (Canada). It stands at Approved on the board, with 1 news move logged; the latest is dated 26 Oct 2026.
- 05ApprovedHere now
- 04FiledApplication submitted to a regulator and under review.
- 03Phase 3Large confirmatory trials meant to support a filing.
- 02Phase 2Does it work at all, and at which dose? Hundreds of patients.
- 01Phase 1First doses in people. Safety, dose range, how the body handles it.
- Company
- Dr. Reddy's Laboratories
- Mechanism
- GLP-1 receptor agonist peptide, generic version of semaglutide
- Given as
- weekly injection
- Lead use on the board
- Type 2 diabetes in adults (Canada)
- Moves logged
- 1latest 8 days ago
Semaglutide generic news moves
-
Generic semaglutide recall in Canada costs its maker 710 million rupees
Dr. Reddy's booked 710 million rupees against revenue for expected returns after an August recall of its semaglutide injection in Canada, on top of a June quarter provision for batches that failed specification.
Other incretins molecules on the board, with their current stage.